Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib versus regorafenib in previously treated advanced GIST
NL-OMON48964Phase 3Completed
- Sponsor
- Blueprint Medicines
- Start
- Apr 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in gastrointestinal stromal tumor (GIST) comparing Avapritinib with Regorafenib (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: completed.
02
Drugs
avapritinibregorafenib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NL-OMON48964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48964.